clobazam (onfi) Report issue

Small molecule Orphan Drug FDA Approved FDA
AACT ChEMBL DrugBank Drug Central Drugs@FDA KEGG MeSH PubChem repoDB

Active Ingredient History

NOW
  • Now
Clobazam belongs to the 1,5-benzodiazepine class of drugs with antiepileptic properties. It has been used to treat anxiety and epilepsy since 1970s. In the US clobazam was approved for marketing in October of 2011 for the adjunctive treatment of seizures associated with Lennox-Gastaut syndrome. It is also approved for adjunctive therapy for epilepsy in patients who have not responded to first-line drugs and in children who are refractory to first-line drugs. The mechanism of action for clobazam is not fully understood but is thought to involve what is known as potentiation of GABAergic neurotransmission resulting from binding at a benzodiazepine site at the GABA(A) receptor. Possible side effects: constipation, fever, drowsiness, sedation, ataxia, aggressive behavior, lethargy, drooling, and irritability. Other side effects include: urinary tract infection, pneumonia, cough, dysphagia, dysarthria, bronchitis, insomnia, fatigue, decreased appetite, and increased appetite.   NCATS

Chemistry

  • SMILES: CN1C2=CC=C(Cl)C=C2N(C3=CC=CC=C3)C(=O)CC1=O
  • InChIKey: CXOXHMZGEKVPMT-UHFFFAOYSA-N
  • Mol. Mass: 300.74
  • ALogP: 3.37
  • ChEMBL Molecule:
    clobazam  
More Chemistry

Pharmacology

Drug Pricing (per unit)

United States

$0.3520 - $46.1166
More Pricing Detail

Note: This drug pricing data is preliminary, incomplete, and may contain errors.

Alternative names

1-phenyl-5-methyl-8-chloro-1,2,4,5- tetrahydro-2,4-diketo-3h-1,5-benzodiazepine | 1-phenyl-5-methyl-8-chloro-1,2,4,5-tetrahydro-2,4-dioxo-3h-1,5-benzodiazepine | 7-chloro-1-methyl-5-phenyl-1,5-dihydro-benzo[b][1,4]diazepine-2,4-dione | clobazam | clobazamum | clobazepam | frisium | frizium | h-4723 | hr 376 | hr-376 | lm-2717 | onfi | perizam | tapclob | urbadan | urbanyl

Organizations (49)

Research & Development (23)

Organization Org Type FDA approvals Clinical Trials involvement Org ID Force Sort

Marketing (27)

Organization Org Type FDA approvals Clinical Trials involvement Org ID Force Sort

Indications (17)

Approved Indications (2)


 

Lennox Gastaut Syndrome (approved 2011)

Seizures

Experimental Indications - Clinical Trial Phases 1-4 (17)


 

Anxiety ()

Anxiety Disorders (Phase 3)

Dementia (Phase 3)

Depression (Phase 3)

Drug Resistant Epilepsy (Phase 4)

Epilepsia Partialis Continua (Phase 3)

Epilepsies, Myoclonic (Phase 3)

Epilepsy (Phase 4)

Epilepsy, Generalized (Phase 3)

Glioma (Phase 4)

Lennox Gastaut Syndrome (Phase 3)

Low Back Pain (Phase 3)

Neuralgia (Phase 1/Phase 2)

Pain (Phase 3)

Psychophysiologic Disorders (Phase 3)

Schizophrenia (Phase 3)

Seizures (Phase 3)

Overview

  • Highest Phase: Phase 4
  • # of Trials: 15
  • # of Trial Organizations: 23

Trials by Phase

Trial Phase Start Date Organizations Indications

Feedback

Data collection and curation is an ongoing process for CDEK - if you notice any information here to be missing or incorrect, please let us know! When possible, please include a source URL (we verify all data prior to inclusion).

Report issue